4th Quarter - Report

ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.

Firm
Client
Income
$10,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Federal research and development funding regarding regenerative medicine products

LobbyistCovered position, as disclosed
DAN RENBERG —
OLIVER SPURGEON III New Legislative Correspondent, Rep. Hank Johnson (2009-2015); Staff Assistant, Rep. Hank Johnson (2007-2009)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic wound healing product

LobbyistCovered position, as disclosed
DAN RENBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions H.R. 1865 (Further Consolidated Appropriations Act, 2020), Division N, Title I, Section 501, regarding medical device excise tax

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
DAN RENBERG —
OLIVER SPURGEON III New Legislative Correspondent, Rep. Hank Johnson (2009-2015); Staff Assistant, Rep. Hank Johnson (2007-2009)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1865 (116th), H.R. 2207 (116th), S. 692 (116th)

Health Issues HCR

Food and Drug Administration policy on chronic wound healing products

LobbyistCovered position, as disclosed
DAN RENBERG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.